Welcome to our dedicated page for Carecloud SEC filings (Ticker: CCLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CareCloud, Inc. (CCLD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed healthcare technology company with common stock (CCLD) and 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock (CCLDO), CareCloud uses SEC filings to report material events, financial results, acquisitions, and capital structure updates.
Investors can review current reports on Form 8-K that describe significant developments such as quarterly earnings releases, preferred stock dividend declarations, acquisitions, and governance matters. For example, recent 8-K filings have covered the announcement of preferred stock dividend payments, the acquisition of Medsphere Systems Corporation and related financial statements, the acquisition of HFMA’s MAP App, and notices regarding Nasdaq listing rule compliance following changes in board composition.
Filings also document financial performance and guidance. Earnings-related 8-Ks incorporate press releases that discuss revenue, profitability, adjusted EBITDA, and management’s expectations, while accompanying exhibits may include presentation slides and non-GAAP reconciliations. These materials help investors understand how CareCloud’s AI-driven and technology-enabled solutions, acquisitions, and operational initiatives affect its financial results.
CareCloud’s SEC disclosures further address preferred stock terms and dividends, including details on its 8.75% Series A and Series B Cumulative Redeemable Perpetual Preferred Stock. Filings and exhibits describe dividend rates, payment schedules, redemption provisions, and, in the case of Series A, events such as mandatory conversion and delisting from Nasdaq when that series no longer met continued listing requirements.
On Stock Titan, AI-powered tools can summarize lengthy filings and highlight key points, such as changes in revenue guidance, acquisition impacts, or updates on preferred dividend plans. Users can quickly scan new 8-Ks, 10-Qs, and 10-Ks as they become available from EDGAR, while also tracking any Form 4 insider transaction reports that may be filed. This page is designed to help readers interpret CareCloud’s regulatory history and stay informed about how corporate actions, acquisitions, AI initiatives, and capital decisions are reflected in its official SEC record.
CareCloud, Inc. director Anne Busquet reported a routine equity award vesting and conversion. On January 31, 2026, 6,250 restricted stock units vested and converted into 6,250 shares of common stock at a price of $0.00 under the company’s Amended and Restated Equity Incentive Plan, without payment by Busquet.
After this transaction, she directly holds 287,638 shares of common stock and 33,750 restricted stock units, reflecting ongoing participation in CareCloud’s long‑term incentive program rather than an open‑market purchase or sale.
CareCloud director Lawrence Steven Sharnak reported the vesting of equity awards and related share issuance. On January 31, 2026, 6,250 restricted stock units converted into 6,250 shares of CareCloud common stock at a price of $0 per share under the company’s Amended and Restated Equity Incentive Plan.
After this transaction, Sharnak directly owned 120,250 shares of common stock and 33,750 restricted stock units. The award vested without cash payment by the reporting person, reflecting compensation delivered in company equity rather than cash.
CareCloud, Inc. director Cameron Munter reported the vesting and conversion of restricted stock units into common stock. On January 31, 2026, 6,250 restricted stock units converted into 6,250 shares of common stock at a price of $0.00 under CareCloud’s Amended and Restated Equity Incentive Plan, without payment by Munter.
After this transaction, Munter directly owned 195,250 shares of CareCloud common stock and 33,750 restricted stock units. The filing reflects equity-based compensation vesting rather than an open‑market purchase or sale.
CareCloud, Inc. furnished an update stating that its Board of Directors has declared monthly cash dividends on its Series A and Series B Cumulative Redeemable Perpetual Preferred Stock. These dividends are scheduled for payment in February, March and April 2026, providing continued cash distributions to holders of these preferred shares during that period. Further details, including the specific dividend terms, are contained in a press release dated January 20, 2026 that is incorporated by reference as an exhibit.
CareCloud, Inc. (CCLD) reported the death of independent director John N. Daly on November 24, 2025. Mr. Daly had served on the Board since July 2014 and was a member of the Audit Committee and chairman of the Compensation Committee.
Because of his passing, the Board no longer has a majority of independent directors and the Audit Committee no longer has at least three members, causing noncompliance with Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)(A). On November 25, 2025, Nasdaq granted a cure period that runs until the earlier of CareCloud’s next annual shareholder meeting or November 24, 2026. The company has informed Nasdaq that the Board plans to appoint an additional independent director to restore compliance.
CareCloud (CCLD) director reported an open-market sale. On 11/10/2025, the reporting person sold 15,000 shares of common stock at a weighted average price of $3.41, with individual trades ranging from $3.40 to $3.43.
Following the transaction, the filer beneficially owns 51,750 shares, held directly. The filing notes that detailed trade breakdowns are available upon request.
CareCloud, Inc. filed a Form 8-K to report that it issued a press release on November 10, 2025. The company furnished the release under Regulation FD as Exhibit 99.1, meaning it is provided for information purposes and is not treated as filed for liability purposes under the Exchange Act.
CareCloud, Inc. filed its Q3 2025 report, showing higher revenue and profitability. Net revenue was $31.067M for the quarter, up from $28.546M a year ago. Operating income was $3.210M and net income was $3.060M. After preferred dividends of $1.365M, net income attributable to common shareholders was $1.695M, or $0.04 per share.
For the nine months, revenue reached $86.076M with net income of $7.910M. Operating cash flow was strong at $19.886M. The balance sheet reflected total assets of $90.576M and shareholders’ equity of $57.804M. As of October 31, 2025, there were 42,397,039 common shares outstanding.
The company closed two acquisitions: Medsphere Systems for $16.5M (including $8.25M cash and $8.25M under a deferred payment that was satisfied on September 3, 2025), adding $11.219M of goodwill; and RevNu with contingent consideration of approximately $649k. CareCloud entered a new $10M secured revolving line with Provident Bank; $6.5M was outstanding at quarter end.
CareCloud, Inc. furnished materials related to its results of operations and financial condition. The company provided a press release and an accompanying slide presentation, delivered under Item 2.02 and Item 7.01, respectively. The materials are furnished and not deemed filed under the Exchange Act.
Exhibits include 99.1 (press release dated November 6, 2025), 99.2 (slide presentation dated November 6, 2025), and 104 (Cover Page Inline XBRL). CareCloud’s securities trade on the Nasdaq Global Market under CCLD (common stock) and CCLDO (8.75% Series B Preferred). The report was signed by Interim CFO and Corporate Controller Norman Roth.
CareCloud, Inc. (CCLD) filed an Amendment No. 1 to Form 8-K to complete its earlier acquisition disclosure for Medsphere Systems Corporation. The amendment adds the required financial statements of the acquired business and unaudited pro forma combined information under Item 9.01(a) and (b).
Exhibits include Medsphere’s audited financials as of December 31, 2024 and 2023, unaudited interim financials as of June 30, 2025, and unaudited pro forma condensed combined information covering the acquisitions of Medsphere, RevNu, and Mesa. Other disclosures from the original report remain unchanged.